drugset / Trial / NCT03723135

Expanded Access for CC-486

NCT03723135

Expanded access Approved for marketing Celgene Corporation

Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Azacitidine Other / unclassified Oral